Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00160628|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : November 26, 2013
A Korean open-label, community-based trial assessing the efficacy and safety of levetiracetam as adjunctive therapy in partial epilepsy.
Similarity with a similar study conducted in Caucasian epileptic subjects will be assessed.
|Condition or disease||Intervention/treatment||Phase|
|Epilepsy, Partial||Drug: Levetiracetam||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Levetiracetam as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy for Bridging Purpose With a Similar Study on Caucasian Epileptic Subjects|
|Study Start Date :||March 2004|
|Actual Primary Completion Date :||October 2004|
|Actual Study Completion Date :||October 2004|
- To evaluate efficacy of levetiracetam in community based practice (seizure frequency per week over 16 weeks).
- To assess safety of levetiracetam
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00160628
|Study Director:||UCB Clinical Trial Call Center||UCB Pharma|